First Trust Nasdaq Pharmaceuticals ETF
FTXH
17 hedge funds and large institutions have $8.52M invested in First Trust Nasdaq Pharmaceuticals ETF in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
21% more capital invested
Capital invested by funds: $7.06M → $8.52M (+$1.46M)
8.82% more ownership
Funds ownership: 40.11% → 48.93% (+8.8%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
6% less funds holding
Funds holding: 18 → 17 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$624K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$554K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$522K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
+$520K |
| 5 |
LPL Financial
San Diego,
California
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
-$652K |
| 2 |
LJAC
L.J. Altfest & Co
New York
|
-$391K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$44K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$17K |
| 5 |
JAWM
J. Arnold Wealth Management
Youngstown,
Ohio
|
-$16K |
FTXH Hedge Fund Activity: Q1 2022 in Review
17 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q1 2022, worth a combined $8.52M — up 21% from $7.06M a quarter earlier.
Fund positioning in FTXH was balanced in Q1 2022: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $624K. The largest seller was Flow Traders U.S., exiting entirely with an estimated $652K sold.
- 17 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q1 2022, down from 18 in Q4 2021.
- Funds reported $8.52M of First Trust Nasdaq Pharmaceuticals ETF stock for Q1 2022, up 21% quarter-over-quarter.
- 3 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q1 2022 and 3 closed out, a net change of 0 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q1 2022 was Susquehanna International Group, an estimated $624K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q1 2022 was Flow Traders U.S., an estimated $652K sold.
Based on aggregated 13F filings for Q1 2022.